image: This is Deep Knowledge Life Sciences' logo. view more
Credit: Deep Knowledge Life Sciences
Deep Knowledge Ventures is partnering with leading scientists at the University of Oxford, University of Cambridge, and Johns Hopkins University to launch an intelligent life sciences investment fund. The Deep Knowledge Life Sciences (DKLS) investment fund will be based in London, and will invest in companies which have breakthrough technologies with practical applications, focusing on the genetics of age related diseases, oncology, personalized and precision medicine and regenerative medicine.
Deep Knowledge Life Sciences will gather eight life sciences portfolio companies of Deep Knowledge Ventures (DKV), including Insilico Medicine and Pathway Pharmaceuticals. Insilico Medicine uses machine learning (ML) and artificial intelligence (AI) for drug discovery and drug repurposing. Insilico Medicine was awarded the Most Promising Company in Healthcare/IT at the Personalized Medicine World Conference in 2015. Pathway Pharmaceuticals uses its product, OncoFinder, to provide personalized cancer treatment using ML to analyze multi-omics datasets. IBM's Watson Health and Pathway Pharma's OncoFinder has recently announced a partnership to improve clinical decision support systems for cancer treatment.
In addition to the for profit ventures, Deep Knowledge Life Sciences will increase its global activity in non-profit initiatives and will use top level expertise from Oxford and Cambridge to expand this activity in developing countries. One such organization includes the Oxford-based Biogerontology Research Foundation (BGRF), a charity organization which sponsors research, articles, and forums regarding treatments for aging and age-related diseases.
Deep Knowledge Life Sciences will combine the insights from the Artificial Intelligence investment system VITAL (Validating Investment Tool for Advancing Life Sciences), with the brightest minds of the world, to achieve the exponential growth in creating analyses and treatments for diseases while de-risking investments. Dmitry Kaminskiy, founder and senior partner of DKLS, stated "We at Deep Knowledge Ventures are proud to converge on the visions of world-class scientists including Chris Lowe, Charles Cantor, Anthony Atala, Alex Zhavoronkov, and Richard Barker and many other academic heavyweights and industry thought leaders to further our understanding of aging and age-related diseases." During the next year, with the expertise of top scientists, DKLS plans to significantly increase its investment activity in this field. Additionally, DKV will provide its extensive organizational resources, and grant access to its advanced tools in machine learning, deep learning, and artificial intelligence to the companies in which it will invest.
While the fund is based in London, it has multiple collaborations and partnerships in San Francisco, New York, Dubai, Mumbai, Moscow, Singapore, and Hong Kong and licenses its platform to other industry players. DKLS aims to create world's most intelligent life-sciences investment fund, which will trigger an exponential revolution in life sciences to benefit all of humanity.
Information is available on the Deep Knowledge Life Sciences (DKLS) website: http://deepknowledge.life For additional information please contact Charlotte Casebourne, the Associate Director of DKLS, c.casebourne@deepknowledge.life
###
About Deep Knowledge Ventures:
Deep Knowledge Ventures is a Hong Kong-based smart investment fund which focuses on disruptive exponential technologies. The fund's areas of interest include biotechnology, artificial intelligence, personalized medicine, big data analytical systems, and innovative fintech. The fund received fame in 2014 when it appointed a virtual smart machine, the Validating Investment Tool for Advancing Life Sciences (VITAL) to its board of directors.
More information can be found on the fund's website: http://deepknowledgeventures.com Brief company video: https://www.youtube.com/watch?v=f5S4ZwW3pEM
About Insilico Medicine, Inc:
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers of Johns Hopkins University in Baltimore. Insilico Medicine utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in oncology, Parkinson's, Alzheimer's, sarcopenia and geroprotectors. Insilico Medicine provides services to a wide range of pharmaceutical and biotechnology companies. More information can be found on the fund's website: http://insilicomedicine.com/ Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8
About Pathway Pharmaceuticals:
Pathway Pharmaceuticals is a Hong Kong-based high tech personalized medicine company. Pathway provides solutions to medical professionals, healthcare providers, and pharmaceutical companies to help make data-driven decisions when selecting cancer therapies for individual patients. Pathway's flagship product is OncoFinder, which uses a unique algorithm to map gene expression data onto known and custom intracellular signaling pathways. In July 2015 Pathway announced a partnership with IBM Watson to improve clinical decision-making support systems for cancer using artificial intelligence.
More information on the Pathway website: http://pathwaypharmaceuticals.com/
More information on the OncoFinder website: http://oncofinder.com
The OncoFinder video: https://www.youtube.com/watch?v=TMz5rWl4Qmc&feature=youtu.be
About the Biogerontology Research Foundation (BGRF):
The Biogerontology Research Foundation seeks to fill a gap within the research community, whereby the current scientific understanding of the aging process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF will fund research which, building on the body of knowledge about how aging happens, will develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age. Addressing aging damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, which are required to improve quality of life in the elderly.
More information can be found on the BGRF website: http://bg-rf.org.uk/